Q-omics provides the consensus-scored VAX2 profile across patient tissues and cancer cell-line models. VAX2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, VAX2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, VAX2 RNA expression shows 15,574 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, and HNSC as cancer lineages where VAX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VAX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VAX2 survival associations across molecular data types. VAX2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VAX2 RNA expression–survival associations across cancer types. High VAX2 expression shows unfavorable associations in ACC, MESO, STAD, BLCA and UVM, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for VAX2 RNA expression.
This table summarizes VAX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for VAX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VAX2 shows higher tumor expression in HNSC, THCA, LUSC, UCEC, LIHC and CHOL. The HNSC box plot shows higher VAX2 RNA expression in tumor versus normal tissue (log2 FC = +1.199, t-test p < 0.001).
This table shows molecular features associated with VAX2 in patient tissues and cancer cell lines. In patient samples, VAX2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, VAX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
